535936-20-0

Upstream product

• 31865-25-5 benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 1440109-97-6 (3R,4R)-1-benzyloxycarbonyl-3-(diallylamino)-4-hydroxypyrrolidine 
• 141-78-6 ethyl acetate 
• 1440109-64-7 (3R,4R)-3-acetoxy-1-(benzyloxycarbonyl)-4-(diallylamino)pyrrolidine 
• 535936-19-7 benzyl (3R,4R)-3-azido-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate 

Downstream Products

• 535936-22-2 C₁₄H₁₅F₃N₂O₄ 
• 1440109-72-7 (3R,4R)-3-(acetamido)-4-acetoxy-1-(benzyloxycarbonyl)pyrrolidine 
• 1203566-76-0 (3R,4R)-1-benzyloxycarbonyl-3-(tert-butoxycarbonylamino)-4-hydroxypyrrolidine 

Relevant academic research and scientific papers

Chemoenzymatic synthesis of orthogonally protected (3R,4R)- and (3S,4S)-trans-3-amino-4-hydroxypyrrolidines

Several orthogonally protected racemic trans-3-amino-4-hydroxypyrrolidines have been easily prepared from N-Cbz-3,4-epoxypyrrolidine. Resolution of each racemic compound was accomplished by means of lipase-catalyzed aminolysis, transesterification or hydr

COMPOUNDS AS CRF1 RECEPTOR ANTAGONISTS

The present invention relates to compounds of Formula I,or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF, receptor antagonists. Compounds of the invention are useful for t

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.